Encapsulation of exemestane in polycaprolactone nanoparticles: Optimization, characterization, and release kinetics

Cancer Nanotechnology

Volumn 4, Issue 4-5, 2013, Pages 57-71

  Kumar, Abhinesh ^a   Sawant, Krutika ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Box Behnken design; Exemestane; Nanoparticles; Polycaprolactone

Indexed keywords

EXEMESTANE; NANOPARTICLE; POLYCAPROLACTONE;

ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DRUG FORMULATION; IN VITRO STUDY; NANOENCAPSULATION; PARTICLE SIZE; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RING OPENING; SUSTAINED DRUG RELEASE; ZETA POTENTIAL;

EID: 84880805673     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-013-0037-4     Document Type: Article

References (59)

1. Abdelwahed W, Degobert G, Stainmesse S, Fessi H (2006) Freeze-drying of nanoparticles: formulation, process and storage considerations. Adv Drug Deliv Rev 58(15): 1688-1713.
2. Aberturas MR, Perez H, de la Ossa D, Gil ME, Ligresti A, De Petrocellis L, Torres AI, Di Marzo V, Molpeceres J (2011) Anandamide-loaded nanoparticles: preparation and characterization. J Microencapsul 28(3): 200-210.
3. Adinarayana K, Ellaiah P (2002) Response surface optimization of the critical medium components for the production of alkaline protease by a newly isolated Bacillus sp. J Pharm Pharm Sci 5(3): 272-278.
4. Ahlin P, Kristl J, Kristl A, Vrečer F (2002) Investigation of polymeric nanoparticles as carriers of enalaprilat for oral administration. Int J Pharm 239(1-2): 113-120.
5. Akhnazarova S, Kafarov V (1982) Experiment optimization in chemistry and chemical engineering. MIR Publications, Moscow.
6. Bae S, Shoda M (2005) Statistical optimization of culture conditions for bacterial cellulose production using Box-Behnken design. Biotechnol Bioeng 90(1): 20-28.
7. Barichello JM, Morishita M, Takayama K, Nagai T (1999) Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25(4): 471-476.
8. Behan N, Birkinshaw C, Clarke N (2001) Poly n-butyl cyanoacrylate nanoparticles: a mechanistic study of polymerisation and particle formation. Biomaterials 22(11): 1335-1344.
9. Bolton S, Bon C (1997) Pharmaceutical statistics: practical and clinical applications, 3rd edn. Marcel Dekker, New York.
10. Box GEP, Hunter WG, Hunter WS (1978) Statistics for experimenters: an introduction to design, data analysis, and model building. Wiley, New York.
11. Breda M, Pianezzola E, Benedetti MS (1993) Determination of exemestane, a new aromatase inhibitor, in plasma by high-performance liquid chromatography with ultraviolet detection. J Chromato 620(2): 225-231.
12. Chacon M, Molpeceres J, Berges L, Guzman M, Aberturas MR (1999) Stability and freeze-drying of cyclosporine loaded poly(d, l lactide-glycolide) carriers. Eur J Pharm Sci 8(2): 99-107.
13. Clemett D, Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59(6): 1279-1296.
14. Corrigan OI, Li X (2009) Quantifying drug release from PLGA nanoparticulates. Eur J Pharm Sci 37(3-4): 477-485.
15. Das M, Sahoo SK (2012) Folate decorated dual drug loaded nanoparticle: role of curcumin in enhancing therapeutic potential of nutlin-3a by reversing multidrug resistance. PLoS One 7(3): e32920.
16. Derringer G, Suich R (1980) Simultaneous optimization of several response variables. J Quality Technol 12(4): 214-219.
17. Dowsett M (1998) Theoretical considerations for the ideal aromatase inhibitor. Breast Cancer Res Treat 49(Suppl 1): S39-S44, discussion S73-37.
18. Dubernet C (1995) Thermoanalysis of microspheres. Thermochim Acta 248: 259-269.
19. Feng S, Huang G (2001) Effects of emulsifiers on the controlled release of paclitaxel (Taxol) from nanospheres of biodegradable polymers. J Control Release 71(1): 53-69.
20. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S (1989) Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55(1): R1-R4.
21. Fonseca C, Simoes S, Gaspar R (2002) Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83(2): 273-286.
22. George Box DB (1960) Some new three level designs for the study of quantitative variables. Technometrics 2: 455-475.
23. Henderson IC, Canellos GP (1980) Cancer of the breast: the past decade (first of two parts). N Engl J Med 302(1): 17-30.
24. Johannessen DC, Engan T, Di Salle E, Zurlo MG, Paolini J, Ornati G, Piscitelli G, Kvinnsland S, Lonning PE (1997) Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study. Clin Cancer Res 3(7): 1101-1108.
25. Joshi SA, Chavhan SS, Sawant KK (2010) Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm 76(2): 189-199.
26. Kashi TS, Eskandarion S, Esfandyari-Manesh M, Marashi SM, Samadi N, Fatemi SM, Atyabi F, Eshraghi S, Dinarvand R (2012) Improved drug loading and antibacterial activity of minocycline-loaded PLGA nanoparticles prepared by solid/oil/water ion pairing method. Int J Nanomedicine 7: 221-234.
27. Lam CX, Savalani MM, Teoh SH, Hutmacher DW (2008) Dynamics of in vitro polymer degradation of polycaprolactone-based scaffolds: accelerated versus simulated physiological conditions. Biomed Mater 3(3): 034108.
28. Lonning PE (1998) Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Res Treat 49(Suppl 1): S45-S52, discussion S73-47.
29. Mainardes RM, Evangelista RC (2005) Praziquantel-loaded PLGA nanoparticles: preparation and characterization. J Microencapsul 22(1): 13-24.
30. Mak KWY, Yap MGS, Teo WK (1995) Formulation and optimization of two culture media for the production of tumour necrosis factor-β in Escherichia coli. J Chem Technol Biotechnol 62(3): 289-294.
31. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321(7261): 624-628.
32. Mehta AK, Yadav KS, Sawant KK (2007) Nimodipine loaded PLGA nanoparticles: formulation optimization using factorial design, characterization and in vitro evaluation. Curr Drug Deliv 4(3): 185-193.
33. Mendes GD, Hamamoto D, Ilha J, Pereira Ados S, De Nucci G (2007) Anastrozole quantification in human plasma by high-performance liquid chromatography coupled to photospray tandem mass spectrometry applied to pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 850(1-2): 553-559.
34. Misra R, Sahoo SK (2010) Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 39(1-3): 152-163.
35. Montgomery DC (2004) Introduction to factorial designs. Design and analysis of experiments. Wiley, New York.
36. Moraes CM, de Matos AP, de Paula E, Rosa AH, Fraceto LF (2009) Benzocaine loaded biodegradable poly-(d, l-lactide-co-glycolide) nanocapsules: factorial design and characterization. Mat Sci Engi B 165(3): 243-246.
37. Musumeci T, Ventura CA, Giannone I, Ruozi B, Montenegro L, Pignatello R, Puglisi G (2006) PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm 325(1-2): 172-179.
38. Myer RH, Khuri AI, Carter WH (1989) Response surface methodology: 1966-1988. Technometrics 31: 137-157.
39. Myer RH, Montogomery DC (2002) Response surface methodology: process and product optimization using designed experiment, 2nd edn. Wiley, New York.
40. Orozco-Castellanos LM, Marcos-Fernández A, Martínez-Richa A (2011) Hydrolytic degradation of poly(ε-caprolactone) with different end groups and poly(ε-caprolactone-co-γ-butyrolactone): characterization and kinetics of hydrocortisone delivery. Polym Adv Technol 22(4): 430-436.
41. Paolicelli P, Prego C, Sanchez A, Alonso MJ (2010) Surface-modified PLGA-based nanoparticles that can efficiently associate and deliver virus-like particles. Nanomedicine 5(6): 843-853.
42. Peppas NA (1985) Analysis of Fickian and non-Fickian drug release from polymers. Pharm Acta Helv 60(4): 110-111.
43. Zhang Q, Xu W, Wang Z (1994) Synthesis of polycaprolactone with two carboxy end groups. J Mat Sci Technol 10: 351-354.
44. Quintanar-Guerrero D, Allemann E, Fessi H, Doelker E (1998) Preparation techniques and mechanisms of formation of biodegradable nanoparticles from preformed polymers. Drug Dev Ind Pharm 24(12): 1113-1128.
45. Rahman Z, Zidan AS, Khan MA (2010) Non-destructive methods of characterization of risperidone solid lipid nanoparticles. Eur J Pharm Biopharm 76(1): 127-137.
46. Ray S (2006) RSM: a statistical tool for process optimization. Ind Tex J 117: 24-30.
47. Ray S, Lalman JA, Biswas N (2009) Using the Box-Behnken technique to statistically model phenol photocatalytic degradation by titanium dioxide nanoparticles. Chem Eng J 150(1): 15-24.
48. Redhead HM, Davis SS, Illum L (2001) Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J Control Rel 70(3): 353-363.
49. Scott LJ, Wiseman LR (1999) Exemestane. Drugs 58(4): 675-680, discussion 681-672.
50. Seju U, Kumar A, Sawant KK (2011) Development and evaluation of olanzapine-loaded PLGA nanoparticles for nose-to-brain delivery: In vitro and in vivo studies. Acta Biomater 7(12): 4169-4176.
51. Seth AK, Misra A (2002) Mathematical modelling of preparation of acyclovir liposomes: reverse phase evaporation method. J Pharm Pharm Sci 5(3): 285-291.
52. Shah N, Chaudhari K, Dantuluri P, Murthy RS, Das S (2009) Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic((R))P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target 17(7): 533-542.
53. Strassmer-Weippl K, Goss PE (2003) Prevention of breast cancer using SERMs and aromatase inhibitors. J Mammary Gland Biol Neoplasia 8(1): 5-18.
54. Theobald AJ (2000) Management of advanced breast cancer with endocrine therapy: the role of the primary healthcare team. Int J Clin Pract 54(10): 665-669.
55. Thode K, Muller RH, Kresse M (2000) Two-time window and multiangle photon correlation spectroscopy size and zeta potential analysis-highly sensitive rapid assay for dispersion stability. J Pharm Sci 89(10): 1317-1324.
56. Yadav KS, Sawant KK (2010) Modified nanoprecipitation method for preparation of cytarabine-loaded PLGA nanoparticles. AAPS PharmSciTech 11(3): 1456-1465.
57. Yallapu MM, Gupta BK, Jaggi M, Chauhan SC (2010) Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells. J Colloid Interface Sci 351(1): 19-29.
58. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ (1999) Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release 59(3): 299-307.
59. Yee L, Blanch HW (1993) Defined media optimization for growth of recombinant Escherichia coli X90. Biotechnol Bioeng 41(2): 221-230.